An Evaluation of the Efficacy of High-dose Hepatitis B Vaccine in Patients Using Biological Agents
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 2
Abstract
Objectives: Hepatitis B virus (HBV) vaccination is efficient in the normal population, whereas lower humoral response rates in immunosuppressed patients. Biological agents used in the treatment of several diseases in recent years are a significant cause of immunosuppression in patients. In this study we aimed to evaluate the efficacy of double-dose HBV vaccination at months 0, 1, 2, and 6 in patients using biological agents. Materials and Methods: The patients who were using biological agents and seronegative for HBV received double-dose HBV vaccine (40 μg) on months 0, 1, 2 and 6, and response rates were assessed. Patients with anti-HBs titers >10 mIU/mL one month after completion of the vaccine plan were regarded as vaccineresponsive. Results: Eighty-four patients were evaluated. Forty patients (47.4%) were men and 44 (52.4%) were women. The mean age of the patients was 43.1±12.5 years. The most common underlying inflammatory rheumatic disease was ankylosing spondylitis at 51.2% (n=43). The most commonly used biological agent was adalimumab at 36.9% (n=31). Vaccine response was achieved in 85.7% (n=72) of the patients, while no response was achieved in 12 patients (14.3%). Sex, comorbidities, type of underlying inflammatory disease and biological agents had no effect on vaccine response. Conclusion: Administration of 40 μg HBV vaccine at months 0, 1, 2, and 6 to HBV seronegative patients using biological agents was found to be effective. This efficacy was found to be independent of the type of biological agent, the time of onset of the biological agent and the length of use of the biological agent.
Authors and Affiliations
Murat Aydın, Firdevs Aksoy, Zehra Yıldırım, İftihar Köksal
Keywords
Related Articles
- EP ID EP688806
- DOI 10.4274/vhd.galenos.2020.2019.0039
- Views 146
- Downloads 0
Intravenous Drug Use Rates and Results of Direct-acting Antiviral Treatment in Prisoner Patients
Objectives: Intravenous drug use (IVDU) is more common in prisoner patients, and this is a global problem. Hepatitis C virus (HCV) infection is higher in prisoners than general population. In our study, we aimed to exami...
Influence of Sustained Virological Response on APRI in Chronic Hepatitis C: is APRI a Marker of Only the Stage of Fibrosis?
Objectives: Aspartate transaminase (AST) to platelet ratio index (APRI) is widely used to predict the stage of liver fibrosis in patients with chronic hepatit C virus (HCV) infection. In this study, we aimed to evaluate...
Correlation between Hepatitis C Virus Antibodies in Saliva and Serum: A Safe Method for Epidemiological Studies
Objectives: Hepatitis C virus (HCV) infection is an increasing public health problem in developing countries. A non-invasive method is required as blood sampling is an invasive method for detecting HCV antibodies. In thi...
Relationship Between Basic Laboratory Results and Fibrosis in Chronic Hepatitis B Patients
Objectives: Liver biopsy (LB) is an important cornerstone in decision to start treatment for chronic hepatitis B (HB). Viral load and liver function tests are performed to determine the most appropriate time. In this stu...
Hepatitis B Virus Infection: Knowledge and Awareness Among the Patients Admitted in a Tertiary Care Hospital in Bangladesh
Objectives: Hepatitis B virus (HBV) infection is a major cause of morbidity and mortality in Bangladesh. An adequate level of knowledge and awareness among the general population is essential in prevention and control of...